

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**Enfortumab vedotin with pembrolizumab for first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following have been identified as equality issues during the scoping process:

- People living in rural areas that require frequent visits to treatment centres may face barriers.
- Sex and age are highlighted as protected characteristics. Disparities between outcomes and mortality have been noted between people based on sex. Inequalities may also rise for different recommendations based on age.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

All protected characteristics will be considered by the committee when making its recommendations. However, the committee can only make recommendations within a technology's market authorisation.

Geographical disparities in access to treatments for untreated locally advanced or metastatic urothelial cancer will be considered within a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** Jasdeep Hayre **Date:** 8 August 2024